DOI: https://doi.org/10.22141/2224-0551.14.0.2019.165516

Diagnostic algorithm and management of children with liver pathology

O.M. Babadzhanyan, L.G. Voloshina, N.V. Pavlenko, O.L. Slobodianiuk

Abstract


The paper deals with the diagnostic algorithm including a comprehensive study, substantiates the necessity to evaluate the results obtained taking into account the age and sex of the child. The article considers the features of management of children with liver pathology and the mechanisms of action of ursodeoxycholic acid on the human body as well as the results of clinical research and observations on the use of the ursodeoxycholic acid for the treatment of children with liver diseases.

Keywords


ursodeoxycholic acid; children; liver diseases

References


Bush H, Golabi P, Younossi ZM. Pediatric Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017 Jun 9;4(6). pii: E48. doi: 10.3390/children4060048.

Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis‐related liver disease. Cochrane Database Syst Rev. 2012 Oct 17;10:CD000222. doi: 10.1002/14651858.CD000222.pub2.

Maggiore G, Riva S, Sciveres M. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood. Minerva Gastroenterol Dietol. 2009 Mar;55(1):53-70.

Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641.

Guarino MP, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol. 2013 Aug 21;19(31):5029-34. doi: 10.3748/wjg.v19.i31.5029.

Hu RT, Wang NY, Huang MJ, Huang CS, Chen DS, Yang SS. Multiple variants in UGT1A1 gene are factors to develop indirect hyper-bilirubinemia. Hepatobiliary Surg Nutr. 2014 Aug;3(4):194-8. doi: 10.3978/j.issn.2304-3881.2014.08.04.

D'Agata ID, Balistreri WF. Evaluation of liver disease in the pediatric patient. Pediatr Rev. 1999 Nov;20(11):376-90; quiz 389-90.

Kringen MK, Piehler AP, Grimholt RM, Opdal MS, Haug KB, Urdal P. Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants. PLoS One. 2014 Feb 28;9(2):e90248. doi: 10.1371/journal.pone.0090248.

Nunnari G, Pinzone MR, Cacopardo B. Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. J Viral Hepat. 2013 Apr;20(4):e131-7. doi: 10.1111/jvh.12029.

Okada K, Shoda J, Taguchi K, et al. Ursodeoxycholic acid stimulates Nrf2_mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G735-47. doi: 10.1152/ajpgi.90321.2008.

Pinheiro NC, Marinho RT, Ramalho F, Velosa J. Refractory pruritus in primary biliary cirrhosis. BMJ Case Rep. 2013 Nov 14;2013. pii: bcr2013200634. doi: 10.1136/bcr-2013-200634.

Shiu TY, Huang HH, Lin HH, et al. Restriction fragment length polymorphism effectively identifies exon 1 mutation of UGT1A1 gene in patients with Gilbert’s Syndrome. Liver Int. 2015 Aug;35(8):2050-6. doi: 10.1111/liv.12785.

Silvério Ade O, Guimarães DC, Elias LF, Milanez EO, Naves S. Are the spider angiomas skin markers of hepatopulmonary syndrome? Arq Gastroenterol. 2013 Jul-Sep;50(3):175-9. doi: 10.1590/S0004-28032013000200031.

Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepat Mon. 2012 Feb;12(2):77-84. doi: 10.5812/hepatmon.829.

Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 2010 Oct;52(4):1274-80. doi: 10.1002/hep.23823.

Abaturov AE, Kryuchko ТA, Krivusha EL, Poda OA. Efficacy of hepatoprotective therapy with the complex drug "Betargin" in children with non-alcoholic fatty liver disease. Sovremennaya pediatriya. 2018;(91):102-110. (in Russian).

Babadzhanian EN. Experience of using ursodeoxycholic acid in children with organic diseases of the liver. Zdorovʹe rebenka. 2015;(62.1):37-41. doi: 10.22141/2224-0551.2.1.62.1.2015.83277. (in Russian).

Babadzhanian EN, Shutova OV, Voloshyna LG, Hansii OB, Kaafarani A, Slobodianiuk OL. Gilbert’s syndrome targeted therapy. Zdorovʹe rebenka. 2017;12(2.1):219-224. doi: 10.22141/2224-0551.12.2.1.2017.100984. (in Ukrainian).

Belousov YuV, Belousova OYu, Babadzhanian EN, Voloshyna LG. Dytjacha gastroenterologija: pidruchnyk [Pediatric gastroenterology: a textbook]. Kharkiv; 2013. 520 p. (in Ukrainian).

Gubergrits NB. Benign hyperbilirubinemia: are they always absolutely benign? Novosti Meditsiny i Farmatsii. 2011;(393-394):3-7. (in Russian).

Dubrovina GM, Botvin’yev OK, Kolotilina AI. Combination of Gilbert's syndrome and gastrointestinal diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):13-21. (in Russian).

Zvenigorodskaia LA, Mel’nikova NV. Lipid-lowering therapy in patients with non-alcoholic fatty liver disease: the place of hepatoprotectors. Gastroenterologiia. Consilium Medicum. 2009;(1):32-36. (in Russian).

El-Rife N, Gottrand F. The role of ursodeoxycholic acid in the treatment of cholestasis in children. Consilium Medicum Ukraina. 2008;(10):20-22. (in Russian).

Skrypnyk IN. Overweight as a basis for NASH and an actual medical and social problem. Zdorov’ja Ukrai'ny. 2009;(225):6-7. (in Russian).

Skrypnik IN, Maslova AS. Benign hyperbilirubinemia. Novosti Meditsiny i Farmatsii. 2012;(431):4-19. (in Russian).

Sorokman TV, Popeliuk О-МВ, Makarova OV. Gilbert’s syndrome: terminology, epidemiology, genetics, pathogenesis (part I). Zdorovʹe rebenka. 2016;(76):82-86. doi: 10.22141/2224-0551.8.76.2016.90830. (in Ukrainian).

Stepanov YuM., Abaturov AYe, Zavgorodnia NYu., Skyrda IYu. Non-alcoholic fatty liver disease in children: current view on diagnostics and treatment (part I). Gastroenterologìa. 2015;(56):58-67. doi: 10.22141/2308-2097.2.56.2015.81504. (in Ukrainian).

Tsimmerman YaS. Primary sclerosing cholangitis: modem concepts. Klinicheskaia meditsina. 2014;92(1):5-11. (in Russian).

Zvenigorodskaia LA, Mel’nikova NV. Lipid-lowering therapy in patients with non-alcoholic fatty liver disease: the place of hepatoprotectors. Gastroenterologiia. Consilium Medicum. 2009;(1):32-36. (in Russian).






Copyright (c) 2019 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта